Afuco™ Anti-Human CD44 ADCC Recombinant Antibody (RG7356), ADCC Enhanced (CAT#: AFC-122CL)
Anti-CD44 ADCC Enhanced Antibody (RG7356) is an ADCC enhanced antibody produced by our Afuco™ platform. RG7356 is a humanized antibody targeting the constant region of CD44 that shows antitumor efficacy in mice implanted with CD44-expressing tumors such as MDA-MB-231 breast cancer cells. Short-term treatment of tumor-bearing mice with RG7356 resulted in modifications of the MAPK pathway in the responsive model, although no effects on downstream phosphorylation were observed in a nonresponsive xenograft model.
Specific Inquiry
Figure 1 Pharmacokinetic assessments.
RG7356 serum concentration versus time plot in patients in Arm A who received the biweekly (q2w) (A) and weekly (qw) (B) dosing schedules
Menke-van der Houven,C.W.,van Oordt,C.G.R.,van Herpen, C.,Coveler, A. L.,Mahalingam, D., Verheul, H. M.,& Cannarile, M. A.(2016).First-in-human phase I clinical trial of RG7356,an anti-CD44 humanized antibody,in patients with advanced, CD44-expressing solid tumors.Oncotarget,7(48),80046.
Figure 2 Waterfall plot showing best response of individual patients according to RECIST criteria.
Of 61 evaluable patients, 21% (13/61) had stable disease (SD) as best response 45 patients had tumor lesion evaluation during the study. Abbreviations: PD (progressive disease); SD (stable disease).
Menke-van der Houven,C.W.,van Oordt,C.G.R.,van Herpen, C.,Coveler, A. L.,Mahalingam, D., Verheul, H. M.,& Cannarile, M. A.(2016).First-in-human phase I clinical trial of RG7356,an anti-CD44 humanized antibody,in patients with advanced, CD44-expressing solid tumors.Oncotarget,7(48),80046.
Figure 3 RG7356 induces a temporary reduction from baseline of CD14+ peripheral blood monocytes after first infusion.
(A),does not seem to have an effect on macrophage tumor infiltration (B), and generates a temporary release in cytokines. The latter seems to be independent of dose and/or dose-schedules (C-F). Dose-limiting toxicities (DLTs) occurred in 3 patients during the study: grade 3 febrile neutropenia on study day 18 and 2 cases of headache on study days 4 and 8 (C-F). Abbreviations: C (cycle); D (day); EOI (end of infusion); IL (interleukin); MCP-1 (monocyte chemoattractant protein-1); q2w (biweekly). A. Plot of mean changes from baseline of percent of CD14+ (± standard deviation) at RG7356 doses ≥300 mg for the q2w schedule. B. Waterfall plot of percent change in CD68+ macrophages. C.-F. Individual cytokine profiles.
Menke-van der Houven,C.W.,van Oordt,C.G.R.,van Herpen, C.,Coveler, A. L.,Mahalingam, D., Verheul, H. M.,& Cannarile, M. A.(2016).First-in-human phase I clinical trial of RG7356,an anti-CD44 humanized antibody,in patients with advanced, CD44-expressing solid tumors.Oncotarget,7(48),80046.
Figure 3 RG7356 induces a temporary reduction from baseline of CD14+ peripheral blood monocytes after first infusion.
The latter seems to be independent of dose and/or dose-schedules (C-D). Dose-limiting toxicities (DLTs) occurred in 3 patients during the study: grade 3 febrile neutropenia on study day 18 and 2 cases of headache on study days 4 and 8 (C-F). Abbreviations: C (cycle); D (day); EOI (end of infusion); IL (interleukin); MCP-1 (monocyte chemoattractant protein-1); q2w (biweekly). A. Plot of mean changes from baseline of percent of CD14+ (± standard deviation) at RG7356 doses ≥300 mg for the q2w schedule. B. Waterfall plot of percent change in CD68+ macrophages. C.-F. Individual cytokine profiles.
Menke-van der Houven,C.W.,van Oordt,C.G.R.,van Herpen, C.,Coveler, A. L.,Mahalingam, D., Verheul, H. M.,& Cannarile, M. A.(2016).First-in-human phase I clinical trial of RG7356,an anti-CD44 humanized antibody,in patients with advanced, CD44-expressing solid tumors.Oncotarget,7(48),80046.
Specifications
- Host Species
- Humanized
- Derivation
- Humanized
- Type
- ADCC enhanced antibody
- Species Reactivity
- Human
- Related Disease
- Chronic Lymphocytic Leukemia; Solid Tumors
Product Property
- Purity
- >98% by SDS-PAGE and HPLC analysis
- Storage
- 4°C or -20°C, avoid repeated freezing and thawing.
Target
- Alternative Names
- CD44; CD44 molecule (Indian blood group); IN; LHR; MC56; MDU2; MDU3; MIC4; Pgp1; CDW44; CSPG8; HCELL; HUTCH-I; ECMR-III; CD44 antigen; epican; Hermes antigen; hyaluronate receptor; phagocytic glycoprotein 1; heparan sulfate proteoglycan; cell surface glycoprotein CD44; extracellular matrix receptor III; chondroitin sulfate proteoglycan 8; GP90 lymphocyte homing/adhesion receptor; hematopoietic cell E- and L-selectin ligand; homing function and Indian blood group system
- Gene ID
- 960
- UniProt ID
- P16070
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "CD44"
Select a product category from the dropdown menu below to view related products.
Please select product type
Humanized Antibody Products
Chimeric Antibody Products
Mouse Antibody Products
Human Antibody Products
Chicken IgY Antibody Products
Blocking Antibody Products
Neutralizing Antibody Products
Rabbit Monoclonal Antibody Products
IgG Antibody Products
Fab Antibody Products
IgM Antibody Products
ADCC Enhanced Antibody Products
ScFv Antibody Products
Antibody Magnetic Beads
Cancer Stem Cell Biomarker Specific Antibody Products
Non-Human Primate (NHP) Antibody Products
ScFv-Fc Chimera Products
Flow Cytometry (FC) related Products
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-727 | Anti-CD44 Recombinant Antibody (Bivatuzumab) | ELISA, FC, IP, FuncS, IF, Neut, ICC | IgG1 |
| TAB-236LC | Anti-Human CD44 Recombinant Antibody (huPTA-4621) | FuncS | Humanized antibody |
| TAB-236LC-S(P) | Anti-Human CD44 Recombinant Antibody scFv Fragment (huPTA-4621) | FC | Humanized antibody |
| TAB-236LC-F(E) | Anti-Human CD44 Recombinant Antibody Fab Fragment (huPTA-4621) | FC | Humanized antibody |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for AFC-122CL. Click the button above to contact us or submit your feedback about this product.
Popular products with customers
Application: ELISA, IP, FC, FuncS, Neut, IF, ICC
Application: IP, IF, FuncS, FC, Neut, ELISA, ICC
Application: IF, IP, Neut, FuncS, ELISA, FC, WB
Application: FC, IP, ELISA, Neut, FuncS, IF, WB
Application: Inhib, Cyt
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC
Application: WB, ELISA, FuncS
Application: ELISA, Inhib, FC
Application: FC, IB, Block, Inhib, FuncS, ELISA, FACS, IP, IF
Application: Neut, ELISA, IF, IP, FuncS, FC
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
